During the study period, Sorafenib, a protein kinase inhibitor with activity against many protein kinases including vascular endothelial growth factor receptors, platelet-derived growth factor receptors, and RAF kinases15,16, was the first-line recommended treatment for advanced-stage HCC according to the BCLC staging system. The gene discussed is WEE1; the disease is hepatocellular carcinoma.